CO5580788A2 - Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas - Google Patents

Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas

Info

Publication number
CO5580788A2
CO5580788A2 CO04051014A CO04051014A CO5580788A2 CO 5580788 A2 CO5580788 A2 CO 5580788A2 CO 04051014 A CO04051014 A CO 04051014A CO 04051014 A CO04051014 A CO 04051014A CO 5580788 A2 CO5580788 A2 CO 5580788A2
Authority
CO
Colombia
Prior art keywords
alkyl
optionally substituted
heteroaryl
aryl
heterocyclyl
Prior art date
Application number
CO04051014A
Other languages
English (en)
Inventor
Charles Cywin
Lee Jinbo
Paul Gregory Roth
Christopher Ronald Sarko
John Roger Snow
Noel Wilson Stewart
Steven S Pullen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO5580788A2 publication Critical patent/CO5580788A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

1.- Un compuesto de la fórmula (I): en el que:R1 es hidrógeno o alquilo;R2 se escoge entre arilo y heteroarilo, estando cada uno de los R2 opcionalmente sustituido con uno o más Ra;R3 es una cadena de alquilo C1-10 ramificada o no ramificada, sustituida opcionalmente con uno o más Rb,o R3 es el grupo:-(CH2)n-L-R6, en el que L se escoge entre un enlace, -NH-C(O)-, -O-C(O)-, -C(O)- y -S(O)m- en el que m es 0, 1 ó 2, y en el que dicho grupo está opcionalmente sustituido con uno o más Rb;en el que R6 se escoge independientemente entre hidroxi, alquilo, alcoxi, alquiltio, aril-alquilo C0-5, ariloxi-alquilo C0-5, heteroaril-alquilo C0-5, cicloalquil-alquilo C0-5, heterociclil-alquilo C0-5 y amino, estando dicho amino opcionalmente mono- o di-sustituido con acilo, alquilo, alcoxicarbonilo, cicloalquil-alquilo C0-5, aril-alquilo C0-5, heteroaril-alquilo C0-5 o heterociclil-alquilo C0-5;n es 1-10;R4 es el grupo:en el que R4 está unido por enlace covalente en la posición 5 ó 6 indicada de la fórmula (I);R5 se escoge entre aril-alquilo C0-5, alquilo, heteroaril-alquilo C0-5, cicloalquil-alquilo C0-5 y heterociclil-alquilo C0-5, estando cada uno de los R5 opcionalmente sustituido con uno o más Rc;R7 es hidrógeno, alquenilo o alquilo;o R5 y R7 conjuntamente con el átomo de nitrógeno al que están unidos, forman:un anillo monocíclico de 4-7 miembros oun anillo bicíclico de 8-14 miembros, en el que cada anillo monocíclico o bicíclico contiene opcionalmente de 1 a 3 heteroátomos adicionales escogidos entre N, O y S y cada uno de los anillos es aromático o no aromático, y en el que cada anillo monocíclico o bicíclico está opcionalmente sustituido con uno o más Rc; ...
CO04051014A 2001-11-09 2004-06-01 Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas CO5580788A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34463601P 2001-11-09 2001-11-09

Publications (1)

Publication Number Publication Date
CO5580788A2 true CO5580788A2 (es) 2005-11-30

Family

ID=23351329

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04051014A CO5580788A2 (es) 2001-11-09 2004-06-01 Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas

Country Status (18)

Country Link
US (1) US6825219B2 (es)
EP (1) EP1448199A1 (es)
JP (1) JP2005509003A (es)
KR (1) KR20040063144A (es)
CN (1) CN1612733A (es)
BR (1) BR0214019A (es)
CA (1) CA2464419A1 (es)
CO (1) CO5580788A2 (es)
EA (1) EA200400595A1 (es)
HR (1) HRP20040416A2 (es)
IL (1) IL161516A0 (es)
MX (1) MXPA04004301A (es)
NO (1) NO20041887L (es)
NZ (1) NZ533310A (es)
PL (1) PL369771A1 (es)
WO (1) WO2003041708A1 (es)
YU (1) YU37904A (es)
ZA (1) ZA200402947B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
FR2851563B1 (fr) * 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US20050176792A1 (en) * 2004-01-14 2005-08-11 Boehringer Ingelheim Pharmaceuticals, Inc. Ketone substituted benzimidazole compounds
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
EP1828144A2 (en) * 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
WO2006068105A1 (ja) * 2004-12-20 2006-06-29 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
EP2457901A1 (en) * 2005-03-14 2012-05-30 High Point Pharmaceuticals, LLC Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
EP1879881A2 (en) * 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
GB0515025D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1957491A2 (en) * 2005-11-12 2008-08-20 Boehringer Ingelheim International GmbH Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors
US20110071130A1 (en) * 2006-05-08 2011-03-24 Pharmacopeia, Inc. 2-aminobenzimidazoles for treating neurodegenerative diseases
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
EP2244706B1 (en) * 2008-02-25 2016-04-06 Merck Patent GmbH Glucokinase activators
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
WO2010126743A1 (en) 2009-04-27 2010-11-04 High Point Pharmaceuticals, Llc SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS
US8450354B2 (en) 2010-03-23 2013-05-28 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as β-secretase inhibitors
CN103168032A (zh) 2010-08-05 2013-06-19 安美基公司 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
WO2013184766A1 (en) * 2012-06-06 2013-12-12 Irm Llc Compounds and compositions for modulating egfr activity
JO3300B1 (ar) * 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
US8828998B2 (en) * 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2890691B1 (en) 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
WO2015081463A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Egfr inhibitor forms
WO2015083059A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Forms of the egfr inhibitor
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
KR101560338B1 (ko) 2014-04-21 2015-10-19 건국대학교 산학협력단 야누스 키나아제 1의 활성을 선택적으로 저해하는 벤조이미다졸 유도체
JP2019510802A (ja) * 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
JP7054681B2 (ja) 2016-06-24 2022-04-14 インフィニティー ファーマシューティカルズ， インコーポレイテッド 組合せ療法
JP7313364B2 (ja) 2018-02-21 2023-07-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体
WO2020201773A1 (en) * 2019-04-05 2020-10-08 Storm Therapeutics Ltd Mettl3 inhibitory compounds
WO2020260252A1 (en) 2019-06-24 2020-12-30 Boehringer Ingelheim International Gmbh New macrocyclic compounds and derivatives as egfr inhibitors
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
CN116444544A (zh) * 2022-01-10 2023-07-18 中国科学院上海药物研究所 苯并咪唑类化合物及其医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3401171A (en) * 1966-03-11 1968-09-10 Smithkline Corp 2-amidobenzimidazoles
CA1094061A (en) 1976-03-19 1981-01-20 Colin C. Beard 5(6)-benzene ring substituted benzimidazole-2- carbamate derivatives having anthelmintic activity
US4191764A (en) 1976-03-19 1980-03-04 Syntex (U.S.A.) Inc. 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity
US4139626A (en) 1976-03-19 1979-02-13 Syntex (U.S.A.) Inc. Anthelmintic 5(6)-benzene ring substituted benzimidazole-2-carbamates
US4312873A (en) 1978-09-29 1982-01-26 Syntex (U.S.A.) Inc. 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity
KR0137959B1 (ko) 1988-09-12 1998-05-15 로버트 에이. 아미테이지 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
GB9107398D0 (en) 1991-04-09 1991-05-22 British Bio Technology Compounds
JP2729545B2 (ja) 1991-06-05 1998-03-18 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料用の処理液及びそれを用いた処理方法
CA2116863A1 (en) 1992-07-03 1994-01-20 Sumio Yokota Condensed heterocyclic derivatives and herbicides
EP0664792B1 (en) 1992-10-14 2000-01-05 Merck & Co. Inc. Fibrinogen receptor antagonists
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69833224T2 (de) 1997-11-10 2006-09-28 Bristol-Myers Squibb Co. Benzothiazole als protein tyrosin-kinase inhibitoren
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
JP5036112B2 (ja) * 1999-10-06 2012-09-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チロシンキナーゼのインヒビターとして有益な複素環化合物
WO2001070705A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US6903126B2 (en) 2001-07-09 2005-06-07 Schering Ag 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
US7132438B2 (en) 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives

Also Published As

Publication number Publication date
US20030144281A1 (en) 2003-07-31
ZA200402947B (en) 2005-01-24
MXPA04004301A (es) 2004-08-11
NZ533310A (en) 2004-12-24
CN1612733A (zh) 2005-05-04
EA200400595A1 (ru) 2004-10-28
NO20041887L (no) 2004-05-07
HRP20040416A2 (en) 2005-04-30
KR20040063144A (ko) 2004-07-12
EP1448199A1 (en) 2004-08-25
US6825219B2 (en) 2004-11-30
IL161516A0 (en) 2004-09-27
CA2464419A1 (en) 2003-05-22
YU37904A (sh) 2006-08-17
JP2005509003A (ja) 2005-04-07
WO2003041708A1 (en) 2003-05-22
PL369771A1 (en) 2005-05-02
BR0214019A (pt) 2004-10-13

Similar Documents

Publication Publication Date Title
CO5580788A2 (es) Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas
AR107966A2 (es) Derivados de pirimidina y piridina inhibidores de la proteína quinasa
PE20090042A1 (es) Analogos de ciclopamina
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR058769A1 (es) Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen.
AR054799A1 (es) Derivados de oxindol
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR063022A1 (es) Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados.
AR053778A1 (es) Compuestos de quinazolina para el tratamiento de desordenes mediados por la proteina quinasa
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
CY1115606T1 (el) Ετεροκυκλικες ενωσεις, μεθοδοι κατασκευης αυτων και χρηση αυτων στη θεραπεια
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
AR049443A1 (es) Derivados de pirrolpiridinas
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20120798A1 (es) Potentes inhibidores de molecula pequena de autofagia
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
DE60132975D1 (de) Neue substanzen und verbindungen als protease-inhibitoren
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
NI200800247A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.

Legal Events

Date Code Title Description
FA Application withdrawn